Stuart J. Cook

Stuart J. Cook

Auto-generated profile, based on publicly available information

Stuart J. Cook

University College Dublin, Belfield, Dublin, Ireland; St. Vincent's University Hospital, Elm Park, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Immunology & Cell Biology
Verified
Journal Article
Closed access
PDF file
SCStuart J Cook
Stuart J Cook
QLQuintin Lee
Quintin Lee
AWAlex Chit Hei Wong
Alex Chit Hei Wong
BSBenjamin C Spann
Benjamin C Spann
JVJonathan N Vincent
Jonathan N Vincent
BRBen Roediger
Ben Roediger

6 February 2020 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
AEAbdullah Al Emran
Abdullah Al Emran
HTHsin-Yi Tseng
Hsin-Yi Tseng
MCMikaela C. Coleman
Mikaela C. Coleman
JTJessamy Tiffen
Jessamy Tiffen
SCStuart Cook
Stuart Cook
Peter HerseyPeter Hersey
Peter Hersey
Melanoma, as for many other cancers, undergoes a selection process during progression that limits many innate and adaptive tumor control mechanisms. Immunotherapy with immune checkpoint blockade overcomes one of the escape mechanisms but if the tumor is not eliminated other escape mechanisms evolve that require new approaches for tumor control. Some of the innate mechanisms that have evolved against infections with microorganisms and viruses are proving to be active against cancer cells but require better understanding of how they are activated and what inhibitory mechanisms may need to be targeted. This is particularly so for inflammasomes which have evolved against many different organisms and which recruit a number of cytotoxic mechanisms that remain poorly understood. Equally important is understanding of where these mechanisms will fit into existing treatment strategies and whether existing strategies already involve the innate killing mechanisms.

1 September 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AEAbdullah Al Emran
Abdullah Al Emran
HTHsin-Yi Tseng
Hsin-Yi Tseng
DGDilini Gunatilake
Dilini Gunatilake
SCStuart J. Cook
Stuart J. Cook
FAFarzana Ahmed
Farzana Ahmed
JTJessamy Tiffen
Jessamy Tiffen

15 June 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NBNayan D. Bhattacharyya
Nayan D. Bhattacharyya
CCClaudio Counoupas
Claudio Counoupas
LDLina Daniel
Lina Daniel
GZGuoliang Zhang
Guoliang Zhang
SCStuart J. Cook
Stuart J. Cook
CFCarl G. Feng
Carl G. Feng
The quality of T cell responses depends on the lymphocytes9 ability to undergo clonal expansion, acquire effector functions, and traffic to the site of infection. Although TCR signal strength is thought to dominantly shape the T cell response, by using TCR transgenic CD4+ T cells with different peptide:MHC binding affinity, we reveal that TCR affinity does not control Th1 effector function acquisition or the functional output of individual effectors following mycobacterial infection in mice. Rather, TCR affinity calibrates the rate of cell division to synchronize the distinct processes of T cell proliferation, differentiation, and trafficking. By timing cell division–dependent IL-12R expression, TCR affinity controls when T cells become receptive to Th1-imprinting IL-12 signals, determining the emergence and magnitude of the Th1 effector pool. These findings reveal a distinct yet cooperative role for IL-12 and TCR binding affinity in Th1 differentiation and suggest that the temporal activation of clones with different TCR affinity is a major strategy to coordinate immune surveillance against persistent pathogens. Key Points TCR affinity determines the speed and magnitude of the CD4+ T cell response. IL-12 rather than TCR affinity controls Th1 effector function acquisition. TCR affinity calibrates cell division to time IL-12Rβ2 upregulation.

26 October 2024 in BMJ Neurology Open
Verified
Journal Article
Open access
PDF file
RCRaymond Cook
Raymond Cook
NDNyssa Chennell Dutton
Nyssa Chennell Dutton
PSPeter A Silburn
Peter A Silburn
LMLinton J Meagher
Linton J Meagher
GFGeorge Fracchia
George Fracchia
PSPaul Silberstein
Paul Silberstein
Objectives: Deep Brain Stimulation (DBS) is an effective, yet underused therapy for people living with Parkinson’s disease (PD) in whom tremor, motor fluctuations and/or dyskinesia are not satisfactorily controlled by oral medical therapy. Fear of vascular complications related to the operative procedure remains a strong reason for both the referrer and patient reluctance. We review the incidence of vascular complications in the first 600 patients with Parkinson’s disease treated at our centre by a single neurologist/neurosurgical team. Methods: Surgical data routinely collected for patients who underwent DBS implantation for the management of PD between the years 2001–2023 was retrospectively reviewed. Incidences of vascular complication were analysed in detail, examining causal factors. Results: Including reimplantations, 600 consecutive DBS patients underwent implantation with 1222 DBS electrodes. Three patients (0.50%) experienced vascular complications. Conclusion: This vascular complication rate is at the low end of that reported in the literature. Risk mitigation strategies discussed include a consistent neurosurgical team, dual methodology target and trajectory planning, control of cerebrospinal fluid egress during the procedure, use of a specialised microelectrode recording (MER)/macrostimulation electrode without an introducing brain cannula and low number of MER passes. A reduced vascular complication rate may improve the acceptability of DBS therapy for both patients and referrers.

15 December 2024 in The Surgeon
Verified
Journal Article
Closed access
SCStuart J. Cook
Stuart J. Cook
KOKieran M. O'DRiscoll
Kieran M. O'DRiscoll
AMAhmed Al Maksoud
Ahmed Al Maksoud
DEDenis Evoy
Denis Evoy
DMDamian McCartan
Damian McCartan
RPRuth S. Prichard
Ruth S. Prichard